Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
313.02B
Market cap313.02B
Price-Earnings ratio
21.63
Price-Earnings ratio21.63
Dividend yield
2.02%
Dividend yield2.02%
Average volume
1.85M
Average volume1.85M
High today
$156.41
High today$156.41
Low today
$152.67
Low today$152.67
Open price
$156.07
Open price$156.07
Volume
1.45M
Volume1.45M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$112.34
52 Week low$112.34

NVS News

TipRanks 12h
Novartis price target raised to CHF 142 from CHF 132 at Citi

Citi analyst Graham Parry raised the firm’s price target on Novartis (NVS) to CHF 142 from CHF 132 and keeps a Buy rating on the shares. Unlock powerful invest...

TipRanks 1d
Novartis: Sell Rating Maintained as Timing-Driven Upside Keeps Risk‑Reward Unfavorable; $111 Price Target Reaffirmed

James Quigley, an analyst from Goldman Sachs, maintained the Sell rating on Novartis AG. The associated price target remains the same with CHF111.00. Unlock po...

TipRanks 1d
Novartis: Buy Rating Reiterated on Q2 Beat, Strong Growth Brands and Pipeline Upside; Price Target Maintained at $140

In a report released yesterday, Sachin Jain from Bank of America Securities reiterated a Buy rating on Novartis AG, with a price target of CHF140.00. Unlock po...

Analyst ratings

50%

of 28 ratings
Buy
35.7%
Hold
50%
Sell
14.3%

More NVS News

TipRanks 1d
Novartis Earnings Call Highlights Growth Amid Headwinds

Novartis AG ((NVS)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with TipR...

Investor's Business Daily 2d
Novartis Bounds For Buy Point. Why Shares Are On The Rise.

Technology Novartis Bounds For Buy Point. Why Shares Are On The Rise. Licensing Novartis (NVS) stock jumped early Tuesday after the drugmaker reported core earn...

Novartis Bounds For Buy Point. Why Shares Are On The Rise.
Benzinga 2d
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline

Adjusted earnings came in at $2.41 per share, topping the analyst consensus estimate of $2.13. Revenue rose to $14.41 billion from $14.05 billion a year earlier...

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
TipRanks 2d
Novartis reports Q2 core EPS $2.41 vs. $2.42 last year

Reports Q2 net sales $14.41B vs. $14.1B last year. Commenting on Q2 2026 results, Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered a solid secon...

Nasdaq 2d
Novartis Q2 Profit Drops, Net Sales Rise; Reaffirms FY26 Guidance

(RTTNews) - Swiss pharmaceutical major Novartis AG (NVS, NOVN.SW) reported Tuesday lower profit in its second quarter, despite higher net sales and volume growt...

Novartis Q2 Profit Drops, Net Sales Rise; Reaffirms FY26 Guidance
Benzinga 6d
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval

On Friday, the U.S. Food and Drug Administration (FDA) granted traditional approval for Novartis AG’s (NYSE:NVS) oral medication, Fabhalta (iptacopan). The tre...

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.